Navigation Links
Neuralstem Completes $5.25 Million Financing
Date:2/18/2010

ROCKVILLE, Md., Feb. 18 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE AMEX: CUR) announced today that it has raised a total of $5,228,000 since the beginning of the year, comprised of a previously disclosed $1.5 million private placement of 646,551 common shares at $2.32, priced at a 30 percent premium over the market on the closing, and approximately $3.7 million from warrant exercises.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

Neuralstem also is pleased to announce that it received notice from the NYSE Amex that the Company is now in compliance with its listing requirements.

"These funds will help to support the development of our stem cell technology, including our ongoing clinical trial at Emory University," stated Richard Garr, President and CEO of Neuralstem. "We are also pleased that the NYSE Amex has recognized the improvement in Neuralstem's financial position."

About Neuralstem, Inc.

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous system diseases including: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease. ALS is a progressive fatal neurodegenerative disease that affects nerve cells in the brain, leading to the degeneration and death of the motor neurons in the spinal cord that control muscle movement. Pre-clinical work has shown that Neuralstem's cells extended the life of rats with ALS (as reported in the journal TRANSPLANTATION, October 16, 2006, in collaboration with Johns Hopkins University researchers), and also reversed paralysis in rats with Ischemic Spastic Paraplegia (as reported in NEUROSCIENCE, June 29, 2007, in collaboration with researchers at University of California San Diego).

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2008 and the quarterly report on form 10-Q for the period ended September 30, 2009.

SOURCE Neuralstem, Inc.

RELATED LINKS
http://www.neuralstem.com

'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
2. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
4. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
5. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
6. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
7. Neuralstem Reports Second Quarter Financial Results and Highlights
8. Neuralstem Fills Key Product Development Position
9. Neuralstem Responds to New StemCells, Inc. Lawsuit
10. Neuralstem Sues StemCells, Inc. Over New Patent
11. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 25, 2016 , ... Lajollacooks4u has become a rising hotspot for specialized team ... its top attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm and Elsevier, ... team-building experience. , Each event kicks off with an olive oil and salt-tasting competition. ...
(Date:5/25/2016)... AZ (PRWEB) , ... May 25, 2016 , ... ... Dr. Michael Fitzmaurice recently became double board-certified in surgery and surgery of the ... 2015. Dr. Fitzmaurice is no stranger to going above and beyond in his ...
(Date:5/25/2016)... , ... May 25, 2016 , ... WEDI, the nation’s ... exchange, today announced that Charles W. Stellar has been named by the WEDI Board ... since January 2016. As an executive leader with more than 35 years of experience ...
(Date:5/24/2016)... Mass. (PRWEB) , ... May 24, 2016 , ... ... heart attacks, diabetes, and traumatic injuries, will be accelerated by research at Worcester ... cells into engines of wound healing and tissue regeneration. , The novel method, ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):